Biogen reports 11th PML case for Tysabri

An eleventh patient taking Biogen Idec and Elan's multiple sclerosis drug Tysabri has developed a potentially deadly brain infection, the company announced in its weekly update on PML cases. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.